LGALS1 and non-small cell lung carcinoma: Albeit LGALS9 has not yet been implicated in NSCLC or in a chemotherapy-refractory phenotype of other tumor cells, various galectins such as galectin-1 and -3 were reported to have a role in driving a chemotherapy-refractory phenotype [48, 49].